Max Healthcare and Monash University Collaborate to Combat Triple-Negative Breast Cancer, ETHealthworld
New Delhi: Max Healthcare and Monash University have signed a Memorandum of Understanding (MoU) to establish a long-term research and academic partnership aimed at accelerating scientific discovery and strengthening clinical training. The agreement is set to build a collaborative framework spanning discovery science, clinical research, and capacity-building programmes.
Under the MoU, both institutions will work jointly on research projects across communicable and non-communicable diseases, with the first flagship initiative centred on triple-negative breast cancer (TNBC)—an aggressive breast cancer subtype with limited targeted treatment options. The collaboration aims to create a strong pipeline from laboratory research to clinical application, combining Monash’s advanced scientific expertise with Max Healthcare’s extensive patient base and clinical insights.
Senior leadership from both organisations, including Dr. Sandeep Budhiraja, Group Medical Director at Max Healthcare, and Professor Roger Daly, Joint Head of Monash University’s Biomedicine Discovery Institute, attended the signing ceremony. They emphasised that the partnership is expected to drive impactful research, improve precision treatment strategies and support the development of future-ready clinical talent.
The agreement also includes provisions for staff and student exchange, co-authored publications, joint education and training modules, and structured academic engagement to build research capacity within India’s healthcare ecosystem. Both institutions aim to foster an integrated environment where clinicians and scientists work collaboratively to address high-burden diseases and accelerate patient-centric innovation.
